Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme

Curr Drug Metab. 2022;23(9):708-722. doi: 10.2174/1389200223666220616125524.

Abstract

Gliomas are the most prevailing intracranial tumors, which account for approximately 36% of the primary brain tumors of glial cells. Glioblastoma multiforme (GBM) possesses a higher degree of malignancy among different gliomas. The blood-brain barrier (BBB) protects the brain against infections and toxic substances by preventing foreign molecules or unwanted cells from entering the brain parenchyma. Nano-carriers such as liposomes, nanoparticles, dendrimers, etc. boost the brain permeability of various anticancer drugs or other drugs. The favorable properties like small size, better solubility, and the modifiable surface of dendrimers have proven their broad applicability in the better management of GBM. However, in vitro and in vivo toxicities caused by dendrimers have been a significant concern. The presence of multiple functionalities on the surface of dendrimers enables the grafting of target ligand and/or therapeutic moieties. Surface engineering improves certain properties like targeting efficiency, pharmacokinetic profile, therapeutic effect, and toxicity reduction. This review will be focused on the role of different surface-modified dendrimers in the effective management of GBM.

Keywords: Glioblastoma multiforme; PAMAM; PLL; PPI; dendrimers; surface engineering.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Blood-Brain Barrier / metabolism
  • Brain / metabolism
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / pathology
  • Dendrimers* / metabolism
  • Dendrimers* / pharmacology
  • Glioblastoma* / drug therapy
  • Glioblastoma* / pathology
  • Glioma*
  • Humans

Substances

  • Dendrimers
  • Antineoplastic Agents